Back to top
more

Signal Genetics, Inc. (MGEN)

(Delayed Data from NSDQ)

$2.83 USD

2.83
113,835

+0.05 (1.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.82 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Viridian Therapeutics, Inc. [MGEN]

Reports for Purchase

Showing records 1 - 20 ( 96 total )

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/17/2020

Daily Note

Pages: 4

When "002" Is Greater Than "001"; MGEN Advancing VRDN-002, HZNP Read-Through

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

12/17/2020

Daily Note

Pages: 3

In-Licensing of Xtend Antibody Technology Announced; Reiterate Neutral Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/24/2020

Company Report

Pages: 33

Assuming Coverage: Taking On Thyroid Eye Disease

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/24/2020

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/17/2020

Company Report

Pages: 4

Moving Beyond SOLAR Winds; Reiterate Neutral Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/29/2020

Daily Note

Pages: 5

New Direction Marked by Acquisition of Viridian Therapeutics; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/06/2020

Company Report

Pages: 4

Preliminary SOLAR Not Expected to Be Compelling; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/06/2020

Company Report

Pages: 7

Initial Cobo/CTCL Ph2 SOLAR Data Lacks Compelling Results; Focus on MRG-229/IPF

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/22/2020

Company Report

Pages: 5

New CEO Positive for Potential Near-Term Deal Making; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/17/2020

Company Report

Pages: 7

Q2 Recap; Pipeline Forging Ahead Despite COVID-Related Delays

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/10/2020

Company Report

Pages: 5

SOLAR Penetrates Through Negative Impacts in 2Q20; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/26/2020

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/24/2020

Company Report

Pages: 8

Cobo Nabs Orphan Drug Designation in ATLL; Next Up Potential Meeting with FDA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/24/2020

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/23/2020

Company Report

Pages: 8

Promising New Preclinical Data for MRG-229 in IPF

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/13/2020

Company Report

Pages: 7

Q1; COVID-19 Impact Potentially Delays Several Clinical and Regulatory Events

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/08/2020

Company Report

Pages: 5

SOLAR Isn?t Shielded From COVID-19 So Expect Topline Data to Take Longer; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

03/16/2020

Company Report

Pages: 5

The Streamlined Strategy Is Poised to Deliver Several Milestones in 2020; Reiterate Buy and $5 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/12/2020

Company Report

Pages: 7

Q4/FY19: Cash Runway Into Q3:21; Cobomarsen/CTCL Ph2 Enrolled - Topline Q3:20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Viridian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/09/2020

Industry Report

Pages: 5

Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party
// eof